U.S. Markets open in 1 hr 46 mins

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3100-0.1300 (-2.93%)
At close: 4:00PM EST

4.2800 -0.03 (-0.70%)
Before hours: 7:22AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.4400
Open4.3800
Bid4.2400 x 1200
Ask4.2800 x 800
Day's Range4.2350 - 4.4100
52 Week Range2.4000 - 5.5800
Volume230,220
Avg. Volume559,340
Market Cap114.909M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.6580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.60
  • We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
    PR Newswire

    Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021. The presentation will be available on demand to conference participants as of January 11.

  • Oramed Reports Positive First in Human Data from Oral Leptin Study
    PR Newswire

    Oramed Reports Positive First in Human Data from Oral Leptin Study

    Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Israel's Ministry of Health for its oral leptin drug candidate. The single dose study evaluated oral leptin's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic (T1DM) patients.